Rag2-KO/hTROP2

Fig.1 Subcutaneous xenograft tumor growth of NCI-N87 in Rag2-KO/hTROP2 mouse model. 

Fig 2. Body weight change and means of body weight of Rag2-KO/hTROP2 mouse model after tumor inoculation.

 Fig.3 Tumor volume of Sacituzumab govitecan-treated Rag2-KO/hTROP2 mice. 

Female, 13-week-old homozygous mice were subcutaneously inoculated in the right flank with NCI-N87 tumor cells (1×10⁷ cells in 50% Matrigel) to establish tumor growth. Randomization began when the mean tumor volume reached approximately 200-250 mm³ (about one week post-inoculation). Mice were randomly assigned to three treatment groups (n = 8 per group): Group 1 received saline, Group 2 received Sacituzumab govitecan at 0.25 mg/mouse twice weekly, and Group 3 received Sacituzumab govitecan at 0.5 mg/mouse once weekly. All treatments were administered for four weeks starting from the day of grouping. Data are presented as mean ± SEM.

Fig.4 Body weight change of NCI-N87-bearing Rag2-KO/hTROP2 mice under the treatment of saline or Sacituzumab govitecan. 

Female, 13-week-old homozygous mice were subcutaneously inoculated in the right flank with NCI-N87 tumor cells (1×10⁷ cells in 50% Matrigel) to establish tumor growth. Randomization began when the mean tumor volume reached approximately 200-250 mm³ (about one week post-inoculation). Mice were randomly assigned to three treatment groups (n = 8 per group): Group 1 received saline, Group 2 received Sacituzumab govitecan at 0.25 mg/mouse twice weekly, and Group 3 received Sacituzumab govitecan at 0.5 mg/mouse once weekly. All treatments were administered for four weeks starting from the day of grouping. Data are presented as mean ± SEM.